Veradermics, Incorporated

NYSE:MANE USA Biotechnology
Market Cap
$583.40K
Market Cap Rank
#37100 Global
#12068 in USA
Share Price
$61.07
Change (1 day)
+7.23%
52-Week Range
$37.03 - $61.07
All Time High
$61.07
About

Veradermics, Incorporated operates as a biopharmaceutical company focused on developing novel therapeutics for dermatologic and aesthetic conditions. The company develops treatments for Pattern Hair Loss affecting adults and children. The company's products include VDPHL01, an oral, non-hormonal treatment for men and women with PHL for chronic hair loss therapy. Additionally, it engages in the de… Read more

Veradermics, Incorporated - Asset Resilience Ratio

Latest as of September 2025: 50.43%

Veradermics, Incorporated (MANE) has an Asset Resilience Ratio of 50.43% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.

Liquid Assets
$9.48 Million
Cash + Short-term Investments
Total Assets
$18.80 Million
All company assets
Resilience Assessment
Very High
Financial Resilience Level

Asset Resilience Ratio Trend (None–None)

This chart shows how Veradermics, Incorporated's Asset Resilience Ratio has changed over time. Compare with other companies' asset resilience ratios.

Liquid Assets Composition Over Time

This chart breaks down Veradermics, Incorporated's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time.

Current Liquid Assets Breakdown

Component Amount % of Total Assets
Cash & Equivalents $0.00 0%
Short-term Investments $9.48 Million 50.43%
Total Liquid Assets $9.48 Million 50.43%

Asset Resilience Insights

  • Very High Liquidity: Veradermics, Incorporated maintains exceptional liquid asset reserves at 50.43% of total assets.
  • This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
  • The company has significant short-term investments, indicating active treasury management.

Veradermics, Incorporated Industry Peers by Asset Resilience Ratio

Compare Veradermics, Incorporated's asset resilience ratio with other companies in the same industry.

Company Industry Asset Resilience Ratio
MedPacto Inc
KQ:235980
Biotechnology 49.82%
Shenzhen CAU Technology Co Ltd
SHE:000004
Biotechnology 6.20%
Pacific Shuanglin Bio pharmacy Co Ltd
SHE:000403
Biotechnology 6.88%
Nanhua Bio Medicine Co Ltd
SHE:000504
Biotechnology 11.93%
Jiangsu Sihuan Bioengineering Co Ltd
SHE:000518
Biotechnology 0.03%
Chengzhi Shareholding Co Ltd
SHE:000990
Biotechnology 6.73%
Hualan Biological EngineeringInc
SHE:002007
Biotechnology 14.68%
Da An Gene Co Ltd of Sun Yat-Sen University
SHE:002030
Biotechnology 4.35%

Annual Asset Resilience Ratio for Veradermics, Incorporated (None–None)

The table below shows the annual Asset Resilience Ratio data for Veradermics, Incorporated.

Year Asset Resilience Ratio (%) Liquid Assets Total Assets Change
No yearly data available.
pp = percentage points